AXL and lung cancer: The requirement for co-development and co-approval of CDx in order to get TKIs approved against these RTK (ROS1, RET, NTRK1, AXL, PDGFR-α) rearrangement lung cancer represents the daunting challenge to successfully translate decades of basic science research into benefit of cancer patients.